WO2008128144A3 - Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci - Google Patents

Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci Download PDF

Info

Publication number
WO2008128144A3
WO2008128144A3 PCT/US2008/060165 US2008060165W WO2008128144A3 WO 2008128144 A3 WO2008128144 A3 WO 2008128144A3 US 2008060165 W US2008060165 W US 2008060165W WO 2008128144 A3 WO2008128144 A3 WO 2008128144A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
transgenic
chimeric protein
monoclonal antibody
domain
Prior art date
Application number
PCT/US2008/060165
Other languages
English (en)
Other versions
WO2008128144A2 (fr
Inventor
Shuang Zhang
Original Assignee
Shuang Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuang Zhang filed Critical Shuang Zhang
Publication of WO2008128144A2 publication Critical patent/WO2008128144A2/fr
Publication of WO2008128144A3 publication Critical patent/WO2008128144A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un ADN codant une protéine chimère qui comprend un domaine transmembranaire et un domaine de liaison Fc extracellulaire et fournit des cellules de myélome transgéniques et des souris transgéniques ayant l'ADN intégré dans leur génome. L'invention propose également des procédés de préparation de cellules de myélome transgéniques et de souris transgéniques exprimant la protéine chimère. L'invention propose en outre des procédés d'utilisation des cellules de myélome transgéniques et des souris transgéniques pour faciliter l'isolation des cellules B produisant des anticorps monoclonaux. De manière spécifique, les cellules produisant des anticorps sont conçues de sorte à exprimer une protéine chimère qui comprend un domaine transmembranaire et un domaine G' de protéine extracellulaire, libérant les cellules liées aux anticorps. Un tel caractère simplifie la sélection ultérieure de cellules produisant des anticorps monoclonaux.
PCT/US2008/060165 2007-04-15 2008-04-14 Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci WO2008128144A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91188907P 2007-04-15 2007-04-15
US60/911,889 2007-04-15

Publications (2)

Publication Number Publication Date
WO2008128144A2 WO2008128144A2 (fr) 2008-10-23
WO2008128144A3 true WO2008128144A3 (fr) 2009-02-12

Family

ID=39864636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/060165 WO2008128144A2 (fr) 2007-04-15 2008-04-14 Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci

Country Status (1)

Country Link
WO (1) WO2008128144A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020005A1 (fr) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Cassette à auto-suppression dépendant de la différenciation régulée par un miarn
EA038931B9 (ru) * 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
CN114134163A (zh) * 2021-11-05 2022-03-04 中国农业大学 单个抗原特异性转基因杂交瘤细胞筛选方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US20030162947A1 (en) * 2001-02-20 2003-08-28 Meagher Richard B. Rapid production of monoclonal antibodies
US20060228710A1 (en) * 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer
US7166423B1 (en) * 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166423B1 (en) * 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US20030162947A1 (en) * 2001-02-20 2003-08-28 Meagher Richard B. Rapid production of monoclonal antibodies
US20060228710A1 (en) * 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer

Also Published As

Publication number Publication date
WO2008128144A2 (fr) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2006117699A3 (fr) Animaux transgeniques et procedes de fabrication d'anticorps recombines
WO2010056948A3 (fr) Anticorps anti-il-6 humanisés
US20200214274A1 (en) Cells, vertebrates, populations & methods
WO2009097006A3 (fr) Hco32 et hco27 et exemples connexes
HRP20170322T1 (hr) Miševi koji stvaraju vl vezne proteine
WO2010046775A3 (fr) Procédés pour produire des anticorps à partir de plasmocytes
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009155180A8 (fr) Anticorps anti-il-6 et leurs utilisations
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2010070145A3 (fr) Procédé de génération de séquences d'immunoglobulines
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7
NZ602209A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
IL191588A0 (en) Anti -a?? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007117410A3 (fr) Animaux transgéniques exprimant des anticorps chimériques destinés à être utilisés pour la préparation d'anticorps humains
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2008003116A3 (fr) Procédé de fabrication d'immunoglobulines
WO2011146891A3 (fr) Cd4 humain à domaine unique, soluble, complètement fonctionnel, à haute affinité, anticorps et protéines hybrides associées
WO2009081285A3 (fr) Anticorps contre le virus de l'hépatite c
WO2006124451A3 (fr) Anticorps anti-il-13, compositions, procedes et utilisations
NZ615441A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
WO2008076255A3 (fr) Lymphopoïétine stromale thymique (tslp) canine et utilisations associées
WO2006135428A3 (fr) Methodes et compositions destinees a induire une reponse immunitaire contre des antigenes multiples
WO2008098917A3 (fr) Nouveaux anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799801

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08799801

Country of ref document: EP

Kind code of ref document: A2